Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class monoclonal antibody targeting TIGIT for the treatment of solid tumors. Partnered programs include bapotulimab, an antibody targeting ILDR2, in Phase 1 development, licensed to Bayer under a research and discovery collaboration and license agreement, and a TIGIT/PD-1 bispecific derived from COM902 (AZD2936) in Phase 1/2 development by AstraZeneca through a license agreement for the development of bispecific and multi-specific antibodies. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets. The most advanced program, COM503 is about to enter pre-IND enabling studies. COM503 is a potential first-in-class, high affinity antibody targeting cytokine biology to enhance anti-tumor immunity in a differentiated manner. Compugen is headquartered in Israel, with offices in South San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. For more information, please visit http://www.cgen.com/. #Immunooncology #Oncology #Immunology #Biotechnology #TIGIT #PVRIG #DNAM1 #ComputationalBiology #DrugDevelopment #Innovation
View Top Employees from CompugenWebsite | http://www.cgen.com |
Ticker | CGEN |
Revenue | $10 million |
Funding | $51 million |
Employees | 80 (74 on RocketReach) |
Founded | 1993 |
Address | Azrieli Center 26 Harokmim St Bldg D, Holon, Tel Aviv, IL |
Phone | +972 3-765-8585 |
Fax | +972 3-765-8555 |
Industry | Biotechnology, Business Services, Cloud Computing, Drug Delivery, Pharmaceuticals, Internet Services, Drug Discovery, Healthcare, Software, Education, Health Care, Information Technology, Organizations, Professional Services, Project Management |
Web Rank | 5 Million |
Keywords | Compugen, Compucanltd, Compugem Israel, Gene Ontoloyg Large Scale, Compugen Revenue |
Competitors | Alector, AnaptysBio, Crystax Pharmaceuticals / Oryzon Genomics, Five Prime Therapeutics, Inc., Xencor |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 325414 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies |
Looking for a particular Compugen employee's phone or email?
The Compugen annual revenue was $10 million in 2023.
Alberto Sessa is the CFO of Compugen.
74 people are employed at Compugen.
Compugen is based in Holon, Tel Aviv.
The NAICS codes for Compugen are [3254, 32, 325414, 32541, 325].
The SIC codes for Compugen are [873, 87].